Everything tagged "animal health" across the TickerSpark archives.
Elanco is showing real momentum from Zenrelia and Credelio Quattro, with stronger pet-health growth, improving margins, and raised EPS guidance. The stock still screens as a Hold because leverage remains elevated and valuation leaves less room for execution missteps.
Zoetis remains a high-quality animal health leader, but slower companion animal demand, heavier discounting, and a reduced 2026 outlook keep the stock in Hold territory. Livestock and diagnostics are offsetting some weakness, yet the earnings reset is still underway.
Phibro Animal Health is executing well after the Zoetis portfolio acquisition, with double-digit sales and EBITDA growth. But elevated leverage and regulatory exposure keep the stock in Hold territory.
Zoetis’ 5.97% selloff looks like a concentrated U.S. pet-demand reset, not a broken animal-health franchise. At 12.39x trailing earnings and a 37.0% operating margin, ZTS offers long-term bulls a better entry than its old premium valuation did.
ELAN’s 8.6% post-earnings drop on 2.8x relative volume looks less like a fresh opportunity than a market warning. The turnaround is real, but the stock is not yet earning a rerating.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime